Immune-checkpoint inhibitors can re-activate the immunogenic effect against cancer cells; programmed cell death protein-1 (PD-1) binds to the PD-L1/2 ligand and can stimulate apoptosis in T-lymphocytes, while CTLA-4 binds to CD28, producing further inhibitory signals. This evidence concerns the gene PDCD1 and cancer.